Abstract
Clinical impact of Ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19+B-cell repopulation
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
https://doi.org/10.1016/j.msard.2021.103287
Copy DOIPublication Date: Sep 27, 2021 | |
Citations: 9 | License type: other-oa |
Clinical impact of Ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19+B-cell repopulation
Join us for a 30 min session where you can share your feedback and ask us any queries you have